A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007912/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the
combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up
to 45 mg/m2 paclitaxel.
提供机构：
Vivli
创建时间：
2022-06-15
